Pomaglumetad methionil

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Schizophrenia

Conditions

Schizophrenia

Trial Timeline

Dec 1, 2011 โ†’ Oct 1, 2012

About Pomaglumetad methionil

Pomaglumetad methionil is a phase 3 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01487083. Target conditions include Schizophrenia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01487083Phase 3Terminated

Competing Products

20 competing products in Schizophrenia

See all competitors
ProductCompanyStageHype Score
antipsychotic dose increaseEli LillyPre-clinical
23
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + AripiprazoleEli LillyApproved
85
olanzapine therapyEli LillyApproved
85
olanzapine-RAIM + placeboEli LillyPhase 2
52
Clozapine + OlanzapineEli LillyApproved
85
AtomoxetineEli LillyApproved
85
Risperidone + Placebo + LY2140023Eli LillyPhase 2
52
Olanzapine + olanzapine + risperidoneEli LillyApproved
85
Zotepine + RisperidoneAstellas PharmaApproved
85
ASP4345 + Matching PlaceboAstellas PharmaPhase 1
33
ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidoneAstellas PharmaPhase 2
52
ASP6981 + PlaceboAstellas PharmaPhase 1
33
SAPHRIS + AsenapineSun PharmaceuticalPhase 1
33
Torrent's Quetiapine Fumarate TabletsTorrent PharmaceuticalsPhase 1
33
Olanzapine HydrochlorideEli LillyPhase 1/2
41
Rapid-Acting Intramuscular Olanzapine + PlaceboEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
Intramuscular Olanzapine Depot + PlaceboEli LillyPhase 3
77
olanzapine + atomoxetine + placeboEli LillyPhase 1/2
41